Refractory immune thrombocytopenic purpura: current strategies for investigation and management
B Psaila, JB Bussel - British journal of haematology, 2008 - Wiley Online Library
B Psaila, JB Bussel
British journal of haematology, 2008•Wiley Online LibraryThere is currently no consensus on how best to manage refractory immune
thrombocytopenic purpura (ITP). In part, this reflects the need for individualized treatment
due to the wide spectrum of patients' requirements and responsiveness to therapies. The
objective of this review is to provide a clinically useful guide to current management
strategies. This article suggests investigations to identify factors that may exacerbate
thrombocytopenia and underlie poor therapeutic responses, and highlights emerging …
thrombocytopenic purpura (ITP). In part, this reflects the need for individualized treatment
due to the wide spectrum of patients' requirements and responsiveness to therapies. The
objective of this review is to provide a clinically useful guide to current management
strategies. This article suggests investigations to identify factors that may exacerbate
thrombocytopenia and underlie poor therapeutic responses, and highlights emerging …
Summary
There is currently no consensus on how best to manage refractory immune thrombocytopenic purpura (ITP). In part, this reflects the need for individualized treatment due to the wide spectrum of patients' requirements and responsiveness to therapies. The objective of this review is to provide a clinically useful guide to current management strategies. This article suggests investigations to identify factors that may exacerbate thrombocytopenia and underlie poor therapeutic responses, and highlights emerging therapies, including the thrombopoietic agents, which are anticipated to dramatically alter the natural history of “refractory” ITP. Morbidity, mortality and heath‐related quality of life are also discussed.
Wiley Online Library
以上显示的是最相近的搜索结果。 查看全部搜索结果